Replies to post #56821 on Anavex Life Sciences Corp (AVXL)

[scottsmith]

Could also be that the company is not as confident in their ability to secure the A plus patent.

[frrol]

Yes they are. I received a responding e-mail from IR that emphasized 2-73 as a monotherapy. So the synergies were not as substantial as once thought. Shows you that we are working with hypotheses here, and how vital clinical testing is to determining actual human efficacy.